NCT06229522Recruiting
Patients Derived Organoids as a Promising Tool to Tailor Ovarian Cancer Therapies (PANDORA).
Patients Derived Organoids as a Promising Tool to Tailor Ovarian Cancer Therapies (PANDORA)
Source: ClinicalTrials.gov · Last updated 29 Jan 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The association of clinical, pathogenesis and mutational profile of patients affected by ovarian cancer have improved the armamentarium of therapies available for medical doctors. One of most remarkable advancements is represented by the introduction of PARP inhibitors in the front-line setting of advanced ovarian carcinoma. It is necessary to continue with this effort and introduce novel approaches to improve the survival rate as well as predictive biomarkers to approved therapies. Given the absence of predictive biomarkers to standard therapy, patients derived organoid could be a promising platform to test clinically available drugs and/or promising new molecules to explore the tumor sensibility in an ex-vivo model. The aim of this study is to correlate treatment sensibility measured in tumor derived organoids to clinical sensibility seen in real world patients.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 150 (estimated)
- First submitted
- 12 Dec 2023
- Start date
- 16 Nov 2023
- Primary completion date
- 31 Dec 2037
- Lead sponsor
- Centro di Riferimento Oncologico - Aviano
- Diseases
- Ovarian cancer
- NCT number
- NCT06229522
What you commit to
- Study type: Observational
- Planned participants: 150
- From 16 Nov 2023 to the primary completion date, 31 Dec 2037
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- History of concomitant or previous malignancy in the last 5 years
Other
- Patients for which the tumor/ascites biobanking process could compromise the diagnostic assessments;
- Pregnancy or breast-feeding
Who the study is looking for
- Signed informed consent form;
- Female sex;
- Age ≥18 years;
- Diagnosis of ovarian cancer;
- Availability of tumor sample or ascites that is planned to be stored in the Institutional Biobank for research purpose
Age in the registry: 18 years to - · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Centro di Riferimento Oncologico (CRO) di Aviano - IRCCS Coordinator of this site? Confirm its status | Aviano | Italy | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.